In a case that could shake the foundation of the pharmaceutical and biotech industries, New Delhi-based generic drugmaker Ranbaxy Laboratories Limited claims that the main patent for Lipitor -- Pfizer's biggest-selling product and the world's most lucrative drug -- does not cover the form of a key ingredient used in the cholesterol-fighting drug. The suit also spotlights Ranbaxy's Jay Deshmukh, a patent attorney who now finds himself playing David to Pfizer's Goliath.
December 30, 2004
This article requires premium access
This article requires premium access to Law.com. Please sign in or subscribe to read the full text.